VACCINES TO TACKLE COVID-19

0
434
VACCINES TO TACKLE COVID-19

Until recently, many individuals were not aware of the word coronaviruses. But the virus and the diseases it causes in animals and humans have been recognized for about 50 years ago. Coronavirus is derived from the Latin word “Corona,” which means “Wreath.” And the only way to tackle these kinds of viruses is the right type of Vaccines.

Vaccination is one of the most cost-effective ways of avoiding any infection. With the case of COVID-19, the whole world is waiting for the vaccination because finding a successful vaccine is the only exit strategy for this global pandemic. A vaccination for COVID-19 will be a critical tool for making a difference by bringing the virus under control with the combination of effective testing and existing safety measures. Researchers from all over the world are working hard to develop a safe and effective vaccine.

Companies Working On COVID-19 Vaccines:

Covid-19, first identified in December in Wuhan, China, 2019, has since affected 64 million people worldwide and killed 1,400,000 till the end of November 2020. Many drug makers and big Life Sciences Consulting NYC companies have stepped forward to develop vaccines to treat those affected with the novel Coronavirus. Let’s take a look at some companies working on the development of the COVID-19 vaccine.

⦁ BioNTech and Pfizer:

BioNTech and Pfizer are working on the development of the Covid-19 vaccination. The vaccine is called the “BNT162 program,” and it is in the first stage. Pfizer Inc. announced that they would help BioNTech in developing and distributing the COVID-19 vaccination. The vaccine has been tested on 360 patients in the U.S, and BioNtech has started the clinical trials in collaboration with Shanghai Fosun Pharmaceutical group Ltd. In China. This particular vaccine is the fastest vaccine to go from idea to reality taking only ten months to develop and go for clinical trials. Hospitals with the facility to store this vaccine in a cold space will be provided with the vaccine by BioNTech and Pfizer.

⦁ Gilead Sciences:

It is best known for its treatment of Hepatitis-C in Sovaldi that changed care quality for that particular disease. Gilead Sciences is working on COVID-19 vaccination called “Remdesivir.” It also received authorization from the Food and Drug Administration (FDA), May, in the U.S, based on the preliminary results from the clinical trials conducted by NIAID and Gilead. In the trials at NIAID, patients affected by COVID-19 were given the vaccination. They recovered in 11 days compared to the 15 days, which is the actual recovery time period for the virus.

⦁ Johnson & Johnson:

Johnson & Johnson announced that they are working with Biomedical Advanced Research and Development Authority (BARDA) to test its vaccine candidate. The company is done with their phase 1 clinical trial, and according to Johnson & Johnson, the new doses of vaccines will be available by early 2021 for emergency use only.

⦁ Moderna:

Moderna Inc. received the funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop an RNA based vaccine against COVID-19. In February 2020, Moderna shipped their first batch to NIAID for Phase 1 clinical trials in the U.S. The clinical trials were successful, and it is expected that the vaccine will be available by the mid of 2021.

⦁ Roche:

Roche Holding AG’s vaccine “Actemra” was approved in 2010 for the treatment of rheumatoid arthritis. Now the company has initiated a phase 3 clinical trial to evaluate the results of Actemra for COVID-19 patients hospitalized with severe pneumonia. In April, the first patient in the clinical trial in partnership with BARDA was treated. According to Roche, the results are expected in the early summer of 2021.

Hydroxychloroquine Sulfate and Chloroquine Phosphate to Treat COVID-19:

VACCINES TO TACKLE COVID-19

A number of different strategies have been tried to treat COVID-19, including antibacterial drugs, glucocorticoids, antiviral drugs, and many more. However, no drug has shown such qualities to treat COVID-19 so far. Recently, two antimalarial drugs, Hydroxychloroquine Sulfate (HCQ) and Chloroquine Phosphate (C.Q.) have been appeared to have potential qualities to treat COVID-19 patients and have achieved successful results in clinical trials too. Food and Development Authority has issued an Emergency Use Authorization for this drug to treat COVID-19 patients.

A Clinical trial in France included 19 patients of COVID-19. They were given a 600 mg daily dose of Hydroxychloroquine Sulfate (HCQ), and they record a significant decrease of the novel virus in the patients. The same team did another clinical study on 80 COVID-19 patients. The results showed that out of 80, only two patients aged 86 and 74 died from the Coronavirus. However, all other patients showed clinical improvement and rapid decline in the virus.

Hydroxychloroquine Sulfate and Chloroquine Phosphate can be used to treat COVID-19, but this drug has a number of adverse reactions also, such as nausea, low blood sugar level, and changes in mood or heavy or incorrect dosage can cause heart attacks or coma. It is important to use this drug with your doctor’s prescription and better results under their supervision.

What Is COVAX?

COVAX is the vaccines pillar of the ACT-Accelerator is a global collaboration to speed up the development and easy access to COVID-19 tests, medicines, and vaccines. Its main aim is to speed up the development of COVID-19 vaccinations and to make sure that there is rational and fair access for every country in the world. Through the COVAX facility, UNICEF is working with the manufacturers on the procurement of COVID-19 vaccines as well as its logistics and storage. It will help in expanding the manufacturing of COVID-19 vaccination in the world. UNICEF is working for the COVAX facility, and they ensure that all countries participating in the COVAX Facility will have fair access to 2 billion doses of the COVID-19 vaccine till the end of 2021.

Who Will Have Access To The COVID-19 Vaccine:

The current objective is to create 2 billion doses of the vaccine accessible for the COVAX Facility countries by the end of 2021. This ought to be sufficient doses to protect health care and social care workers, as well as those at high risk of getting affected by the Coronavirus. That will be a huge achievement, but likely for the first few years, there won’t be enough doses for the vaccination available. Which means it will be vital to continue taking other safety measures to protect yourself, your family, and your community, continue practicing physical distancing, regular handwashing, and wearing masks to tackle COVID-19.

Author Bio:

Name: William Patrick Slattery

VACCINES TO TACKLE COVID-19

Email: [email protected]

William Patrick Slattery is the President, and CEO of Nieuw Amsterdam Advisors, a life sciences consulting firm. He is regarded as one of the top marketing experts in the Life Sciences industry noted for combining a calm demeanor with a shrewd negotiation skill set that allows for navigating the most challenging business environments on behalf of his client firms.

LEAVE A REPLY

Please enter your comment!
Please enter your name here